263769-22-8Relevant articles and documents
Process development toward the pilot scale synthesis of the piperidine-based cocaine analogue and potent dopamine and norepinephrine reuptake inhibitor CTDP 31,446
Mobele, Bingidimi I.,Kinahan, Taryn,Ulysse, Luckner G.,Gagnier, Steven V.,Ironside, Michael D.,Knox, Graham S.,Mohammadi, Farahnaz
, p. 914 - 920 (2012/12/23)
(+)-Methyl 4β-(4-chlorophenyl)-1-methylpiperidine-3α-carboxylate hydrochloride (CTDP 31,446) is known as a dopamine reuptake inhibitor. This cocaine analogue lacking the tropane skeleton is being considered for potential treatment of cocaine addiction. Herein we report the development of a scalable process for the preparation of this compound. This study was mainly aimed at improving the process throughput, eliminating chromatographic purifications for the separation of (±)-6-cis isomer from (±)-6-trans isomer, and developing a robust crystallization for isolation of pure (±)-6-cis in a single crop with a good mass recovery. The process development work also highlights an efficient recycle of (±)-6-trans via a kinetic epimerization followed by crystallization of the resulting (±)-6-cis isomer. The resolution of (±)-6-cis and the crystallization of the final HCl salt were optimized and implemented to afford CTDP-31,446 with high purity and good mass recovery.
Monomeric and dimeric heterocycles, and therapeutic uses thereof
-
, (2008/06/13)
The invention provides compounds of formula (I):X—L—X1??(I)wherein X and X1 are substituted piperidine, cyclohexane, or tetrahydropyran rings, and L is a linking group between X and X1; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson's disease, depression, or a disease wherein the administration of cocaine is indicated, comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.
Analogs of cocaine
-
, (2008/06/13)
The invention provides a compound of formula (I): STR1wherein R 1, R 2, R 3, and Y have any of the meanings defined in the specification; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson''s disease or depression comprising administering a compound of formula I, to a mammal in need of such treatment.
Synthesis and biological evaluation of 1-azabicyclo-[3.2.1]octanes: New dopamine transporter inhibitors
Tamiz, Amir P.,Smith, Miles P.,Enyedy, Istvan,Flippen-Anderson, Judith,Zhang, Mei,Johnson, Kenneth M.,Kozikowski, Alan P.
, p. 1681 - 1686 (2007/10/03)
The synthesis and biological activity of a series of 6-substituted 1-azabicyclo[3.2.1]octanes are described. 1-Azabicyclo[3.2.1]octanes represent a new class of compounds that exhibit monoamine transporter inhibitory activity highly dependent on the overall topology and the absolute stereochemistry of the molecule. (C) 2000 Elsevier Science Ltd. All rights reserved.
Chemistry and pharmacology of the piperidine-based analogues of cocaine. Identification of potent DAT inhibitors lacking the tropane skeleton
Kozikowski, Alan P.,Araldi, Gian Luca,Boja, John,Meil, William M.,Johnson, Kenneth M.,Flippen-Anderson, Judith L.,George, Clifford,Saiah, Eddine
, p. 1962 - 1969 (2007/10/03)
To discover agents that might be useful in the treatment of cocaine abuse, we have chosen to re-explore a class of molecules that was first reported by Clarke et al. in 1973 and that was and shown to lack locomotor stimulatory activity in mice. These compounds are piperidine-3-carboxylic acid esters bearing a 4-chlorophenyl group in position 4, and as such, these structures may be viewed as truncated versions of the WIN series compounds, i.e., they lack the two-carbon bridge of the tropanes. All members of this class were synthesized starting from arecoline hydrobromide and obtained in optically pure form through resolution methods using either (+)- or (-)- dibenzoyltartaric acid. Interestingly, we have found that these piperidines do, in fact, exhibit substantial affinity in both WIN 35,428 binding at the dopamine transporter and in the inhibition of [3H]dopamine uptake. Of all of the compounds synthesized, the 3-n-propyl derivative (-)-9 was found to be the most potent with a binding affinity of 3 nM. This simple piperidine is thus 33-fold more potent than cocaine in binding affinity and 29-fold more potent in its inhibition of dopamine uptake. Although no efforts have presently been made to 'optimize' binding affinity at the DAT, the substantive activity found for the n-propyl derivative (-)-9 is remarkable; the compound is only about 10-fold less active than the best of the high- affinity tropanes of the WIN series. As a further point of interest, it was found that the cis-disubstituted piperidine (-)-3 is only about 2-fold more potent than its trans isomer (+)-11. This result stands in sharp contrast to the data reported for the tropane series, for the epimerization of the substituent at C-2 from β to α has been reported to result in a lowering of activity by 30-200-fold. This smaller spread in binding affinities for the piperidines may reflect the smaller size of these molecules relative to the tropanes, which allows both the cis and the trans isomers to adjust themselves to the binding site on the DAT. Our present demonstration that these piperidine structures do, in fact, possess significant DAT activity, taken together with their reported lack of locomotor activity, provides a compelling argument for exploring this class of molecules further in animal behavioral experiments. The present work thus broadens the scope of structures that may be considered as lead structures in the search for cocaine abuse medications.
